Comparing the detection rate of saturated bx and MRI/US Fusion Target Bx in patients with previous negative prostate biopsy between

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20110903007457N19

Enrollment

Registered

2018-05-16

Start date

2018-04-16

Completion date

Unknown

Last updated

2018-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diagnostic test for prostate cancer detection/ Saturated biopsy / MRI/US Fusion Targeted Biopsy. Malignant neoplasm of prostate

Interventions

Intervention group: The study contains two distinct group. All of the patients who entered to the survey will exist PSA serum level more than 4ng/dl or abnormal digital rectal exam and also primary ne

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Elevated serum PSA more than 4 or abnormal digital rectal exam Negative primary prostate biopsy

Exclusion criteria

Exclusion criteria: Patients with evidence suggesting advanced prostate cancer such as bone pain, suspicious evidence in CT scan or Bone scan

Design outcomes

Primary

Measure	Time frame
Number of detected prostate cancer. Timepoint: The timeline of measuring in our study is reporting specimen by pathologist after sampling. Method of measurement: Measuring variable is based by definite pathology report indicating presence prostate cancer or not. In cancer cases Gleason score is also noted.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNasser Shakhssalim

Shahid Beheshti University of Medical Sciences

shakhssalim@unrc.ir+98 21 2256 7222

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026